BRISTOL MYERS SQUIBB
- Country
- 🇫🇷France
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
A Study to Assess the Absorption of a Single Dose of BMS-986205 in Healthy Volunteers When Administered as a Crushed Tablet Orally or Crushed Tablet Suspension Via Nasogastric Tube, as Compared to a Tablet
- Conditions
- Healthy Volunteers
- Interventions
- Drug: BMS-986205
- First Posted Date
- 2017-12-05
- Last Posted Date
- 2018-02-23
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 40
- Registration Number
- NCT03362411
- Locations
- 🇺🇸
PPD Austin Clinic, Austin, Texas, United States
A Study of Continuous Infusions of HNO (Nitroxyl) Donor in Patients With Heart Failure and Impaired Systolic Function
- Conditions
- Heart FailureCardiac FailureReduced Ventricular Ejection Fraction
- Interventions
- First Posted Date
- 2017-11-30
- Last Posted Date
- 2020-07-27
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 49
- Registration Number
- NCT03357731
- Locations
- 🇺🇸
Orange County Research Center, Tustin, California, United States
🇺🇸Brigham and Womens Hospital, Boston, Massachusetts, United States
🇺🇸Inova Heart and Vascular Institute, Falls Church, Virginia, United States
An Investigational Immuno-Therapy Study of Experimental Medication BMS-986242 Given in Combination With Nivolumab in Patients With Advanced Cancer
- Conditions
- Cancer
- Interventions
- Drug: BMS-986242Biological: Nivolumab
- First Posted Date
- 2017-11-22
- Last Posted Date
- 2020-08-26
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 7
- Registration Number
- NCT03351231
- Locations
- 🇺🇸
Local Institution, Baltimore, Maryland, United States
🇺🇸University Of Alabama At Birmingham, Birmingham, Alabama, United States
🇺🇸USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer
- Conditions
- Squamous Cell Carcinoma of the Head and Neck
- Interventions
- First Posted Date
- 2017-11-21
- Last Posted Date
- 2021-08-09
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 74
- Registration Number
- NCT03349710
- Locations
- 🇺🇸
Cancer Treatment Centers of Phoneix, Goodyear, Arizona, United States
🇺🇸Pinnacle Research Group, Llc, Anniston, Alabama, United States
🇺🇸UCLA Health, Los Angeles, California, United States
A Study to Evaluate the Effect of 2 Drugs on the Pharmacokinetics of BMS-986205 in Healthy Subjects
- Conditions
- Malignancies Multiple
- Interventions
- First Posted Date
- 2017-11-17
- Last Posted Date
- 2018-02-28
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 53
- Registration Number
- NCT03346837
- Locations
- 🇺🇸
PPD, Austin, Texas, United States
An Investigational Study to Assess the Effect of BMS-986177 on Aspirin in Healthy Participants
- First Posted Date
- 2017-11-14
- Last Posted Date
- 2018-01-19
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 20
- Registration Number
- NCT03341390
- Locations
- 🇺🇸
PPD Austin Clinic, Austin, Texas, United States
An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2017-11-09
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 292
- Registration Number
- NCT03338790
- Locations
- 🇺🇸
Local Institution - 0037, Miami, Florida, United States
🇺🇸Local Institution - 0009, Marietta, Georgia, United States
🇺🇸Local Institution - 0012, Detroit, Michigan, United States
A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer
- Conditions
- Advanced Pancreatic Cancer
- Interventions
- Drug: Nab-paclitaxelBiological: CabiralizumabBiological: NivolumabDrug: OnivydeDrug: FluorouracilDrug: OxaliplatinDrug: GemcitabineDrug: LeucovorinDrug: Irinotecan Hydrochloride
- First Posted Date
- 2017-11-08
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 205
- Registration Number
- NCT03336216
- Locations
- 🇺🇸
Local Institution - 0006, Philadelphia, Pennsylvania, United States
🇺🇸Local Institution - 0007, Los Angeles, California, United States
🇺🇸Dana Farber Cancer Institute., Boston, Massachusetts, United States
A Study of Experimental Medication BMS-986235 in Healthy Subjects
- Conditions
- Mediators of Inflammation
- Interventions
- Drug: BMS-986235Other: Placebo
- First Posted Date
- 2017-11-07
- Last Posted Date
- 2022-03-31
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 122
- Registration Number
- NCT03335553
- Locations
- 🇺🇸
PRA Health Sciences, Salt Lake City, Utah, United States
🇺🇸Anaheim Clinical Trials, Anaheim, California, United States
An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment
- Conditions
- Advanced Cancer
- Interventions
- Biological: NivolumabBiological: IpilimumabDrug: IDO1 InhibitorBiological: RelatlimabBiological: CabiralizumabRadiation: Radiation Therapy
- First Posted Date
- 2017-11-07
- Last Posted Date
- 2022-09-26
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 20
- Registration Number
- NCT03335540
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸Local Institution - 0001, Chicago, Illinois, United States
🇺🇸Local Institution - 0003, Pittsburgh, Pennsylvania, United States